About this episode

This episode discusses pivotal clinical trials presented at ASCO 2026 that could change cancer treatment practices.

This episode is the ASCO 2026 Plenary Episode. This week, all of the pivotal, game-changing, life-changing trials are discussed here. Some describe the plenary session as practice-changing, and we will always agree that better treatments with significant improvements in life expectancy and quality of life need their time in the spotlight. Today, five trials are discussed, including SARC041, a liposarcoma study utilising the CDK 4/6 inhibigtor abemacicilib. Our second study is HARMONI-6, investigating whether ivonescimab plus chemotherapy is effective in patients with advanced squamous non-small cell lung cancer. Our third, almost like something written for an opera (LIBRETTO0-432), a lung cancer trial looking at selpercatinib in those with RET fusion early-stage NSCLCa. PROTEUS emerges as our fourth trial, rising from the depths of the ocean to evaluate apalutamide in the perioperative prostate cancer space. Finally, and most importantly in our opinion, is RASolute302, the pancreatic cancer trial, showing that even the most difficult mutation is now treatable. An incredible story of an exceptionally difficult cancer to treat, Daraxonrasib is the star of this year's ASCO. Studies…

More episodes of Oncology for the Inquisitive Mind

• 207. ASCO 2026 - Agents of the Future - Part 2 · July 5, 2026 · 1h 4m
• 206. ASCO 2026 - Part 1 · June 28, 2026 · 1h 2m
• 205. ESTRO update with A/Prof Steven David · June 14, 2026 · 23 min

Explore listener stats, chart rankings, contacts and more on the Oncology for the Inquisitive Mind podcast page.